Yes, Pyxis Oncology is a publicly traded company. It completed its initial public offering and is officially listed on the Nasdaq Global Select Market under the ticker symbol PYXS. As a clinical-stage biopharmaceutical enterprise focused on developing next-generation antibody-drug conjugates and immunotherapies, its common shares can be freely bought and sold by retail and institutional investors through standard brokerage accounts during normal market trading hours.